Medicines Australia is committed to the transparency of its conduct in administering the Code of Conduct. As required in the Code, Medicines Australia publishes information about complaints considered by the Code and Appeals Committee in the last three years.

Complaint Outcomes

Complaint 1177 – MONOFER Promotional Material, published April 2025
Complaint 1176 – UTROGESTAN Promotional Material, published April 2025
Complaint 1174 – BREZTRI Promotional claims, published November 2024
Complaint 1173 – ERLYAND Promotional claim, published March 2024
Complaint 1172 – NUBEQA Media Statement, published December 2023
Complaint 1171 – LAGEVRIO Promotional material, published November 2023
Complaint 1170 – REVILIMID Patient communication, published July 2023
Complaint 1169 – EPCLUSA Promotional material + activities, published April 2023
Complaint 1168 – TRELEGY ELLIPTA Promotional material + abuse of the Code, published March 2023

Medicines Australia publishes all complaints which have been adjudicated by the Code of Conduct Committee in the last three years. Where the Committee does not adjudicate the complaint, such as being onwardly referred or withdrawn, Medicines Australia does not publish the outcome of that complaint. They are tabled in Medicines Australia’s Annual Reports.

Contact information & confidentiality

Members of the Code of Conduct committees will not discuss complaints with a healthcare professional, member of the general public or pharmaceutical company.

All questions relating to particular complaints or the Code of Conduct more broadly should be directed to the Secretary of the Code of Conduct Committee at Medicines Australia.
Phone: (02) 6147 6500
Email: codehelpdesk@medicinesaustralia.com.au